GAITHERSBURG, Md. — January 29, 2026 — Leads & Copy —
Altimmune, Inc. (Nasdaq: ALT) has finalized its registered direct offering, securing approximately $75 million before fees, according to a press release. The biopharmaceutical company will use the net proceeds towards its upcoming Phase 3 trial in MASH as well as for working capital and general corporate purposes.
The company, which is focused on therapies for liver diseases, entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof).
The offering’s shares and pre-funded warrants are being offered by Altimmune. The pre-funded warrants have an exercise price of $0.001 per share, are exercisable immediately upon issuance and will not expire until fully exercised.
Jerry Durso, President and Chief Executive Officer of Altimmune, stated that the investment will strengthen Altimmune’s balance sheet and increase operational and strategic flexibility as the company moves toward initiating its Phase 3 trial. He also noted Pemvidutide’s potential as a differentiated therapy for MASH patients, citing Phase 2b data and the FDA’s Breakthrough Therapy Designation.
Titan Partners, a division of American Capital Partners, acted as the sole placement agent for the offering.
The securities were offered pursuant to an effective shelf registration statement previously filed with the SEC, which was declared effective on December 5, 2025. A prospectus supplement has been filed with the SEC and is available on its website.
This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities, nor will there be any sale of securities in any jurisdiction where such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for serious liver diseases. Their lead candidate, pemvidutide, targets both glucagon and GLP-1 receptors for the treatment of MASH, AUD, and ALD.
Source: Altimmune
